Biomedical subjects

Dana G Carroll

Publications and source records attributed to Dana G Carroll.

4 recordsLinked to original sources

PubMed2006

Nonhormonal therapies for hot flashes in menopause.

Numerous reports in the medical literature and popular media have discussed the effectiveness of various nonhormonal agents in reducing menopausal hot flash symptoms. Data for these therapies are limited, and most of the studies have been conducted in women with a history of breast cancer. Selective serotonin reuptake inhibitors and venlafaxine have been shown to reduce hot flashes by 19 to 60 percent and were well tolerated by study participants. Soy isoflavones reduced hot flashes by 9 to 40 percent in some trials, but most trials showed no difference compared with placebo. Black cohosh and red clover also have had inconsistent results, with some trials showing benefit and some no difference compared with placebo. Soy isoflavones, black cohosh, and red clover were well tolerated in clinical trials. Other agents that have been used to alleviate hot flashes include belladonna/ergotamine tartrate/phenobarbital combination, dong quai, evening primrose oil, gabapentin, ginseng, mirtazapine, trazodone, vitamin E, and wild yam, but few data regarding their effectiveness have been published. Further randomized controlled trials are needed.

Cimicifuga↗

PubMed2004

Role of topiramate for the treatment of painful diabetic peripheral neuropathy.

OBJECTIVE: To review the possible role of topiramate for the treatment of neuropathic pain and, specifically, the pain of diabetic peripheral neuropathy. DATA SOURCES: Clinical studies and abstracts were identified by using PubMed (January 1966--October 2003), Ovid (January 1966--December 2003), and International Pharmaceutical Abstracts (January 1970--December 2003) and by reviewing bibliographies of published studies. Key search terms included pain, peripheral neuropathy, diabetes, and topiramate. English-language studies were identified, as were pertinent references from these articles. DATA SYNTHESIS: Published data are limited on the successful use of topiramate in the treatment of neuropathic pain syndromes, and only three prospective studies evaluated the effectiveness of topiramate in diabetic peripheral neuropathy. In addition, the use of topiramate to treat diabetic neuropathic pain syndromes successfully may be limited by patients' inability to tolerate the adverse effects associated with the agent. CONCLUSIONS: Topiramate has been used successfully in relieving the pain of various neuropathies, including painful diabetic peripheral neuropathy. Randomized controlled trials that specifically focus on the use of topiramate in patients with painful diabetic peripheral neuropathy are needed to confirm the initial findings in case reports, abstracts, and small clinical trials that have focused on treating numerous neuropathic pain syndromes, including diabetic peripheral neuropathy.

Adult↗

PubMed2003

Painful diabetic peripheral neuropathy relieved with use of oral topiramate.

Diabetic peripheral neuropathy affects 5 to 50% of people with diabetes in the United States. It is a progressive disorder that results in a gradual decrease in peripheral sensation and eventually complete loss of sensation. Patients with diabetic peripheral neuropathy are challenging to treat because of intolerable adverse medication effects and the development of tolerance to medical treatment. We present the case of a patient with peripheral neuropathy that was unresponsive to usual therapies. She experienced significant relief with the administration of topiramate. Topiramate is an anticonvulsant that is gaining recognition in the treatment of patients with neuropathic pain syndromes.

Administration, Oral↗

PubMed2002

Hormone replacement therapy: current concerns and considerations.

AUDIENCE: This activity is designed for pharmacists and other healthcare professionals who evaluate and treat perimenopausal and postmenopausal women. GOALS: To understand the benefits, risks, and adverse effects associated with estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) and their influence on a postmenopausal woman's initiation, adherence, and satisfaction with therapy. OBJECTIVES: 1. Discuss menopause and its effects. 2. Identify ERT/HRT's potential benefits and risks. 3. Discuss ERT/HRT's adverse effects and management approaches. 4. Identify various administration routes for ERT/H RT. 5. Identify currently available ERT/HRT products. 6. Recognize potential reasons for lack of initiation and continuation as well as ways to improve adherence in patients.

Aged↗